07.01.25 -- Lonza Bets The House On Biologics. What's It Mean For You?

20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We're confident you don't need 20/20 vision to see the value in this! Join us for Outsourced Pharma's July Partner Week – including sessions in Cell & Gene Therapy, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free.

Gain the insight and strategic flexibility needed to confidently navigate the unique scientific, regulatory, and documentation challenges of gene therapy development.

The following preclinical IND-enabling oncology studies, conducted by scientists over the past decade, highlight the role of robust preclinical models in advancing the fight against cancer.

Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.

Outsourced Pharma Live explored the specific challenges of biologics development that are pushing CDMOs to adopt more flexible approaches. The discussion covered key factors such as customized manufacturing solutions, adaptive project timelines, and responsive technology integration to help ensure that development and manufacturing at CDMOs stay on track in an unpredictable environment.

Review how BACS can streamline T cell isolation, reduce costs, and enhance CAR T and TCR cell therapy manufacturing.

Streamline development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.

Examine how a standardized cryopreservation process is transforming leukapheresis handling by reducing risk and improving quality across the cell therapy supply chain.

Low AAV production and the lack of platform processes continue to be key challenges driving up costs. Review a robust and scalable suspension manufacturing platform for AAV production.

Advance your mRNA development and strengthen your response to emerging health threats with next-generation, cell-free DNA template solutions designed for speed, quality, and reliability.

Watch to gain valuable insights into the successful development and manufacturing of cell and gene therapy-based products.

Consider several gene editing technologies — TARGATT, Mad7, and Base Editing — and gain insights into their transformative applications in genetic engineering and therapeutic development.

With industry-leading viral expertise, we navigate the evolving field of virotherapy to support the manufacturing of your gene therapies, viral vector vaccines, and oncolytic viruses (OVs).

Accelerate your gene therapy pipeline with our cost-effective, high-quality lentiviral vectors, optimized for clinical and commercial success.

Confidently navigate every stage of development with tailored tech transfer solutions supported by proven expertise. Observe how to de-risk, scale, and optimize your process for high-quality performance.

Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.

Utilize our innovative EpyQ™ AAV production system or conventional triple transfection for scalable solutions across all AAV serotypes.

Witness how cell expansion occurs with the world-leading cell line from AskBio, as we are the only company globally licensed to manufacture for third parties.

Learn the regulatory expectations for biopharmaceutical characterization along with the specific requirements for some of the more common modalities that are currently in development.

Our gene therapy viral vector process manufacturing capabilities are designed to rapidly progress your products from gene to market through the development of reproducible cGMP practices.